Pharmacokinetics (PK) is the branch of pharmacology that describes how the body handles a drug—from absorption through distribution and metabolism to excretion. The term is derived from the Greek words for drug and movement, aptly describing how an active substance is transported through the body, transformed, and eliminated. In contrast to pharmacodynamics, which describes what a drug does in the body, pharmacokinetics describes what the body does to the drug. Pharmacokinetic data are an indispensable and regulatory requirement in clinical drug development and form the scientific and regulatory basis for dosing recommendations, dosing intervals, interaction warnings, and administration instructions in the product information.
The Four ADME Processes
Pharmacokinetics is classically divided into four sub-processes, summarized under the acronym ADME: Absorption, Distribution, Metabolism, and Excretion. Absorption describes how and to what extent the active substance enters the systemic circulation from the site of administration. In oral administration, factors such as solubility, membrane permeability, first-pass effect, and gastrointestinal motility play a crucial role.
Distribution describes how the active substance is distributed throughout the body after absorption. The volume of distribution (Vd) is a pharmacokinetic parameter that indicates the extent to which a drug is distributed into tissue. Metabolism encompasses the biochemical transformation of the active substance, primarily in the liver by enzymes of the cytochrome P450 family. Metabolism can produce active or inactive metabolites, which must also be characterized pharmacokinetically and pharmacodynamically, as active metabolites can exert independent therapeutic or toxic effects. Excretion describes the elimination of the active substance and its metabolites from the body, primarily via the kidneys and bile.
Pharmacokinetic Parameters
A series of characteristic parameters are derived from pharmacokinetic studies that are of central importance for clinical development and product information. The maximum plasma concentration (Cmax) and the time of its occurrence (Tmax) describe the absorption profile. The area under the concentration-time curve (AUC) is a measure of the total exposure of the body to the active substance. The half-life (t½) indicates how long it takes for the concentration of the active substance in plasma to decrease by half and is crucial for determining the dosing interval.
Bioavailability (F) describes the fraction of the administered dose that is actually systemically available. For intravenous administration, it is by definition 100%. For oral administration, it can be significantly reduced by first-pass effect, absorption problems, and instability in the gastrointestinal tract. Specific regulatory guidelines from EMA and FDA apply to bioavailability studies and bioequivalence studies, governing study design, subject numbers, and statistical analysis.
Pharmacokinetics in Clinical Development
Pharmacokinetic studies are conducted in all phases of clinical development. In Phase I, first-in-human studies are the focus, characterizing the PK profile of the new active substance in humans for the first time. In Phase II and Phase III, population pharmacokinetic analyses (PopPK) are employed, analyzing PK data from larger and more heterogeneous patient populations and describing the influence of covariates such as renal function, hepatic function, age, and body weight on pharmacokinetics.
Pharmacokinetic-pharmacodynamic (PK-PD) modeling links exposure data with efficacy and safety endpoints and enables model-based dose finding. Regulators at EMA and FDA increasingly use PK-PD models to derive evidence-based dosing recommendations for special populations such as children, elderly patients, or individuals with impaired renal or hepatic function, without having to conduct separate clinical studies for each subgroup. Full-service CROs such as mediconomics support sponsors in planning and conducting pharmacokinetic studies as well as PK-PD modeling within clinical development.
Interactions and Special Populations
Pharmacokinetic interactions occur when two or more drugs are administered simultaneously and mutually influence their absorption, distribution, metabolism, or excretion. Inhibitors or inducers of cytochrome P450 enzymes can significantly alter the systemic exposure of an active substance and cause clinically relevant over- or underdosing. Interaction studies are a mandatory component of the clinical development program and must be documented in the product information.
Special populations such as children, elderly patients, and individuals with renal or hepatic impairment frequently exhibit altered pharmacokinetic profiles. Reduced enzyme activity, altered renal function, and different body composition influence the metabolism and elimination of the active substance. Regulators therefore require PK studies in these populations or the use of population pharmacokinetic models to derive adapted dosing recommendations. Without these data, restrictions in the product information or even regulatory requirements for certain patient groups may result.
Frequently Asked Questions (FAQ)
What is the difference between pharmacokinetics and pharmacodynamics?
Pharmacokinetics describes what the body does to the drug—absorption, distribution, metabolism, and excretion. Pharmacodynamics describes what the drug does to the body—the biological effect, mechanism of action, and dose-response relationship. In modern drug development, both areas are considered in an integrated manner within PK-PD models.
Why Is Half-Life Important for Dosing?
The half-life determines how quickly an active substance is eliminated from the body and how long it takes after initiation of treatment to reach a steady state with stable plasma concentration. Active substances with a short half-life must be dosed more frequently to maintain a stable plasma level. Active substances with a long half-life can be administered once daily or less frequently, which improves patient compliance. The half-life is therefore a central criterion in the development of dosing regimens.